Ocrevus Zunovo™

Understanding OCREVUS ZUNOVO®

OCREVUS ZUNOVO® (ocrelizumab) is a monoclonal antibody designed to target CD20-positive B cells, a key component in the immune system’s attack on the central nervous system in Multiple Sclerosis (MS). It is used to treat Relapsing Forms of MS (RMS) and Primary Progressive MS (PPMS), helping to slow disease progression and reduce relapses.

How OCREVUS ZUNOVO® Works:

• Targets and depletes CD20-positive B cells, reducing immune system attacks on nerve cells.
• Lowers relapse rates in patients with Relapsing MS (RMS).
• Slows disability progression in Primary Progressive MS (PPMS).
• Reduces inflammation in the brain and spinal cord, helping to preserve neurological function.

FDA Approval:

• 2017 – Approved for Relapsing MS (RMS) and Primary Progressive MS (PPMS).

For more information, please visit the Ocrevus Zunovo™ patient website and speak with your healthcare provider to determine if Ocrevus Zunovo™ is the right treatment option for you.